Liraglutide Biosimilar (Levim Biotech)

利拉鲁肽生物类似药 (Levim Biotech)

Report date: 2025/01/06 14:18:21

Base Information

Drug NameLiraglutide Biosimilar (Levim Biotech)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLevim Biotech LLP
China Registration ClassN/A

Develop Information

Active CompaniesLevim Biotech LLP
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A